Apyx Medical CG MedTech, Diagnostics and Digital Health & Services Forum 2026
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good morning, everyone, and thank you for joining us at the Canaccord Genuity MedTech and Diagnostics Conference. My name is Caitlin Roberts, and I am one of the MedTech analysts here at Canaccord Genuity. With us today is Apyx Medical, a medical technology company specializing in helium plasma energy solutions for minimally invasive cosmetic and surgical procedures. With me today is Apyx's CEO, Charlie Goodwin. Before we begin, I want to remind anyone of any relevant disclosures, which can be found on our conference and our firm website. With that, I will turn it over to Charlie.
Thank you, Caitlin. Thank you, everybody, for attending today. I appreciate it. We are Apyx Medical. I am Charlie Goodwin. I am the CEO, and we are and will be the leader in surgical aesthetics, and I will walk you through that market and let you know about what we are doing and why we think it is incredibly important. If you look at aesthetics and you look at the entire market, the market is actually a vast and big market, but we are actually focused on the surgical side of aesthetics. Why did we pick surgery? Because we believe that in aesthetics, that surgery is the only thing that provides durable and transformational results when you are looking at the thing. We believe that we are uniquely positioned for this market because of the disruption that has happened because of the GLP-1 drugs.
The GLP-1 drugs obviously have massive weight loss implications, and the skin sags, and most of those patients are going to require some form of surgical procedure. Historically, we have been a one-technology company, and that technology is Renuvion. Renuvion has been a technology that has over 100 clinical papers that talk about the safety and efficacy of the device for tightening skin after liposuction in a body contouring procedure. We believe that it should be used in every liposuction that is on the marketplace today. But Renuvion also has a lot more utility. In fact, just this September, we came out with a brand-new paper that talks about the cold atmospheric plasma portions of Renuvion and the benefits of forming elastin after use underneath the skin.
We saw patients that had elastin formation of more than 30% and also a reduction of inflammation, and that speaks to the regenerative effects of Renuvion and actually begs the question that if any of these procedures are going on, a patient should have Renuvion use, and that was a brand-new paper that just came out in September of this year. We also just launched last year, we launched AYON, which is, we will talk more about AYON here in a bit, but AYON is the ultimate body contouring device on the marketplace today. It has the two best forms of liposuction, and we launched that in May of last year, and then in May of this year, we just finished it, if you will, because we launched the power-assisted hand piece that just came out in May of 2026.
That definitely rounds out AYON for us, and we are incredibly happy to have the entire system now available in the marketplace. In our last earnings report that we just had last week, we are very proud, too, that the company, over the last 12 months, is actually EBITDA positive, and it has been a tremendous job by the team to get us there. We, over the first three quarters of this year, have still grown the business at 26%. It has been a nice job from the entire team. When you look at this market, I mentioned before how much this market has changed and been disrupted by the GLP-1 drugs, and you can see the study from McKinsey. It talks about those drugs being a $100 billion market by 2030.
I do not know that anybody is really questioning that now as these drugs become more and more prevalent. The big thing about the people on these drugs is that 63% of the patients that are on these drugs are going to be new to aesthetics. You are going to see a massive inflow of people over the next decade that are going to be coming to surgeons to look for solutions on how to take care of their body after the weight loss that they have had. Because of that, you are seeing that med spa revenue in the marketplace has been down, and that makes a lot of sense to us because a lot of those technologies are not going to be suitable for the GLP-1 patients. You are seeing that for market trends. You are also seeing a huge, huge shift in procedures.
We just got brand-new ISAPS data. It is actually not in here yet, but if you look last year, breast lifts were up 48% to over 1 million done annually in the U.S. It is not off a small number. It is off a very large number. Breast lifts being up 48% makes a lot of sense to us because women typically on GLP-1 drugs, the two areas that they lose weight first are their breasts and their butts, and they are usually the two areas that they would not like to lose weight.
You are starting to see this procedural shift, and with that procedural shift, you are actually seeing a lot of combination now procedures to where they are doing incisional work, and then they are combining it with liposuction and Renuvion to contour the entire body because these patients on these drugs are providing more challenge to the surgeons to be able to do that, and that is where surgeons need state-of-the-art technologies, and they need the best things that they can do to do that. Not a surprise to anybody, but if you look at Google Trends and you look at all of the things, the most searched item now around aesthetics is skin tightening. Everybody wants to know how they can tighten their skin and how they can make their appearance look better.
That is where, as I mentioned earlier, the study that we just put about the formation of elastin is incredibly important. We have got to do a good job now as a company, making sure that consumers understand that, because if I can grow more elastin, I can have tighter skin. So, there is all of this stuff that is going on in the marketplace. It has been a big disruption in the marketplace from the patient side, from the provider side, and even from the company side. But we believe that we are incredibly well-positioned to take advantage of this for many years to come. Excuse me. This is the Google Trends data that I talked about, and if you just look at it, you can see in aesthetics what people are searching for.
They are searching for skin tightening, loose skin, liposuction, and body contouring, and you can see all of that is high, and it continues to keep going up from a consumer point of view. The market that we are playing in is massive. It is even almost ridiculous for me to put this slide up here to talk about a $10 billion marketplace, and we are going to do basically $60 million in revenue this year as a small company. But it is a massive market, and it is going to continue to keep growing. As I mentioned before, we were a single-technology company in Renuvion, and the picture that you see up there right now is the generator, which is obviously a piece of capital, and then the wand over on the right side of the photo is a single-use disposable.
About 50% of our revenue as a company comes from that single-use disposable, and that is still the case today. So, it has got a very durable business, and it is nice to, as an aesthetics company, to have such a high portion of our revenue to come from the consumable side of things. Just going to show you a little bit here quickly of how Renuvion works. The probe that you see there is a 3 millimeter probe, and it goes right into the same defect that they have typically done when they have done the liposuction, and it usually is used after liposuction. And if you look at the middle picture there, those white bands are collagen bands, and the yellow balls are fat. And so typically, they have taken the fat out via liposuction, and then they go in with the probe, and they heat the collagen to 85 degrees C.
That heating of the collagen causes maximum contraction. It is like taking a rubber band that has been stretched out and heating it and having it contract. That contraction is what you see and what you notice when you look at the skin, and you can see the tighter skin. And then the body keeps improving on that. It goes through a neocollagenesis process that takes about six to nine months after that. So, you see initial contraction right after the procedure, right on the table, but it is the gift that keeps on giving because your body keeps forming more collagen, and you see it get better and better over time. And what aesthetic presentation would not be without some before and after pictures? But you can see how the results of using liposuction and Renuvion are transformational to this patient. This gentleman obviously did not have much of a jawline.
Obviously, they took some liposuction, and they did that. They only removed 100 ml of fat, so it wasn't a ton of fat in there. But more importantly, they came in with the Renuvion and tightened the skin after, and obviously, he looks a lot younger. He has a jawline and looks great.
Quick question. Do you have a before and after, excluding Renuvion, if a person just did lipo and then didn't do the skin tightening? What is the incremental benefit?
Yeah. Any pics on that?
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
